{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:25:39Z","timestamp":1783470339830,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["108TMU-TMUH-12"],"award-info":[{"award-number":["108TMU-TMUH-12"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["110TMU-TMUH-17"],"award-info":[{"award-number":["110TMU-TMUH-17"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["DP2-111-21121-01-O-07-02"],"award-info":[{"award-number":["DP2-111-21121-01-O-07-02"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Whether valacyclovir-associated neurotoxicity (VAN) occurs more frequently in patients with end-stage renal disease (ESRD) on dialysis is unknown. This is the first population-based study to examine the risk of VAN associated with ESRD patients on dialysis. Among 2,284,800 patients diagnosed as having herpes zoster from 2002 to 2016, patients with ESRD on dialysis and individuals with normal renal function were enrolled in this study. Following propensity score matching, we compared the risk of altered mental status between valacyclovir users and non-users in the ESRD and normal renal function cohorts over a 30-day follow-up period. In the ESRD cohort, the incidence of altered mental status was 1.68 and 0.52 per 1,000 person-day in valacyclovir users and non-users, respectively, with an adjusted hazard ratio (HR) of 3.22 (95% confidence interval [CI]: 2.04\u20134.99, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). The incidence of altered mental status of valacyclovir users on hemodialysis (HD) and peritoneal dialysis (PD) was higher than that of non-users. The adjusted HR was 3.20 (95% CI: 1.98\u20135.15, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) for those on HD and 3.44 (95% CI: 1.13\u201310.49, <jats:italic>P<\/jats:italic> = 0.030) for those with PD. However, altered mental status was not observed in patients on HD receiving \u2264500 mg of valacyclovir three times per week or in those on PD receiving \u2264500 mg of valacyclovir per day. The findings demonstrate that adjusting the valacyclovir dosage and monitoring VAN in patients with HD and PD who have herpes zoster is crucial.<\/jats:p>","DOI":"10.3389\/fmed.2022.997379","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:59:49Z","timestamp":1663653589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Valacyclovir-associated neurotoxicity among patients on hemodialysis and peritoneal dialysis: A nationwide population-based study"],"prefix":"10.3389","volume":"9","author":[{"given":"Yi-Chun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Lin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1053\/j.ajkd.2011.10.049","article-title":"Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study.","volume":"59","author":"Kuo","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster.","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011503.pub2","article-title":"Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.","volume":"11","author":"Schuster","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1468-1331.2008.02527.x","article-title":"Valacyclovir neurotoxicity: clinical experience and review of the literature.","volume":"16","author":"Asahi","year":"2009","journal-title":"Eur J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000046241","article-title":"Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.","volume":"21","author":"Izzedine","year":"2001","journal-title":"Am J Nephrol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03250.x","article-title":"Valacyclovir neurotoxicity can be effectively managed by hemodialysis.","volume":"18","author":"Kambhampati","year":"2011","journal-title":"Eur J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00007691-199808000-00005","article-title":"Neurotoxicity caused by valacyclovir in a patient on hemodialysis.","volume":"20","author":"Linssen-Schuurmans","year":"1998","journal-title":"Ther Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5414\/cnp58168","article-title":"Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis.","volume":"58","author":"Okada","year":"2002","journal-title":"Clin Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/0886022X.2012.743914","article-title":"Intensification of peritoneal dialysis improves valacyclovir neurotoxicity.","volume":"35","author":"Pipili","year":"2013","journal-title":"Ren Fail."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220678","article-title":"Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis.","volume":"2017","author":"Prasad","year":"2017","journal-title":"BMJ Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/0971-4065.127915","article-title":"Valacyclovir associated neurotoxicity in a patient on dialysis.","volume":"24","author":"Singh","year":"2014","journal-title":"Indian J Nephrol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007611","article-title":"Association between stroke risk and metformin use in hemodialysis patients with diabetes mellitus: a nested case-control study.","volume":"6","author":"Chien","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/MAO.0000000000001967","article-title":"Sudden sensorineural hearing loss in hemodialysis patients could be a marker of pathogenic progression in the mortality and atherosclerotic events: a national cohort study.","volume":"39","author":"Chou","year":"2018","journal-title":"Otol Neurotol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021270","article-title":"Risks of all-cause mortality and major kidney events in patients with new-onset primary open-angle glaucoma: a nationwide long-term cohort study in Taiwan.","volume":"8","author":"Chou","year":"2018","journal-title":"BMJ Open."},{"key":"B15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.arcmed.2014.01.009","article-title":"Long-term outcomes of dialysis patients after coronary revascularization: a population-based cohort study in Taiwan.","volume":"45","author":"Chou","year":"2014","journal-title":"Arch Med Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121705","article-title":"Increased risks of mortality and atherosclerotic complications in incident hemodialysis patients subsequently with bone fractures: a nationwide case-matched cohort study.","volume":"10","author":"Kuo","year":"2015","journal-title":"PLoS One."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/ndt\/gfr464","article-title":"Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan.","volume":"27","author":"Lin","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002487","article-title":"Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study.","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092708","article-title":"Long-term effects of ketoanalogues on mortality and renal outcomes in advanced chronic kidney disease patients receiving a low-protein diet.","volume":"12","author":"Wang","year":"2020","journal-title":"Nutrients."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/sim.3150","article-title":"A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.","volume":"27","author":"Austin","year":"2008","journal-title":"Stat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data.","volume":"14","author":"Seeger","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1681\/ASN.2018010096","article-title":"Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients.","volume":"29","author":"Ishida","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s10227-002-0140-3","article-title":"Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections.","volume":"7","author":"Wu","year":"2003","journal-title":"J Cutan Med Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.12998\/wjcc.v7.i20.3329","article-title":"Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: a case report and literature review.","volume":"7","author":"He","year":"2019","journal-title":"World J Clin Cases."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1128\/AAC.00116-07","article-title":"Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.","volume":"51","author":"Garre","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","article-title":"Overview of acyclovir pharmacokinetic disposition in adults and children.","volume":"73","author":"Blum","year":"1982","journal-title":"Am J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/jac\/dkl067","article-title":"The aciclovir metabolite cmmg is detectable in the csf of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.","volume":"57","author":"Hellden","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/ndt\/gfg119","article-title":"High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study.","volume":"18","author":"Hellden","year":"2003","journal-title":"Nephrol Dial Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/cid\/civ930","article-title":"Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease.","volume":"62","author":"Tseng","year":"2016","journal-title":"Clin Infect Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.997379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:59:53Z","timestamp":1663653593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.997379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.997379"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.997379","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"997379"}}